Open-Label absorption, distribution, metabolism, excretion (ADME) and pharmacokinetics (PK) following a Single Oral Dose of AZD1236 in Healthy Male Subjects

Study identifier:D4260C00010

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

An Open-Label. Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics following a Single Oral Dose of 60 mg of [14C] AZD1236 in Healthy Male Subjects

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

14C-AZD1236

Sex

Male

Actual Enrollment

4

Study type

Interventional

Age

50 Years - 65 Years

Date

Study Start Date: 01 Oct 2009
Primary Completion Date: -
Estimated Study Completion Date: 01 Nov 2009

Study design

Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2009 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria